PharmaMar is starting a new Phase III trial, with patients suffering from small cell lung cancer (SCLC). It’ll test the efficacy of its third candidate obtained from marine organisms (PM1183) as a SCLC treatment.
Now, PM1183 is under the spotlight. This cancer drug will be used in a second Phase III trial (after ovarian cancer). It’ll enrol 600 patients with small cell lung cancer (SCLC), for whom platinum-based treatments have failed before.
This type of lung cancer is less common than non-small cell lung cancer (which has very bad statistics) but has the worst prognosis for pulmonary cancers. Five years after diagnosis, only 5% to 10% of the patients are still alive.